<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577040</url>
  </required_header>
  <id_info>
    <org_study_id>10-2020urol</org_study_id>
    <nct_id>NCT04577040</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Tadalafil vs. Tadalafil With Sildosin in the Management of Moderately and Severely Symptomatic Patients of Prostatic Hyperplasia</brief_title>
  <official_title>Safety and Efficacy of Tadalafil vs. Tadalafil With Sildosin in the Management of Moderately and Severely Symptomatic Patients of Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menoufia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menoufia University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study Safety and efficacy of Tadalafil vs. Tadalafil with Sildosin in the management of&#xD;
      moderately and severely symptomatic patients of prostatic hyperplasia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction Benign prostatic hyperplasia (BPH) is a common cause of lower urinary tract&#xD;
      symptoms (LUTS) in middle-aged and elderly men, and the incidence rate of LUTS associated&#xD;
      with BPH (LUTS/BPH) increases with age.&#xD;
&#xD;
      LUTS can be broadly grouped into: (i) storage symptoms, such as frequency, urgency, and&#xD;
      nocturia (ii) voiding symptoms, such as intermittency, weak stream and straining, and (iii)&#xD;
      post-micturition symptoms, such as a feeling of incomplete emptying and post micturition&#xD;
      dribble.&#xD;
&#xD;
      For optimal management of LUTS/BPH, medications should be chosen based on age, disease&#xD;
      progression, need for long-term management, and other clinical parameters.&#xD;
&#xD;
      Alpha 1 adreno-receptors antagonists (alpha 1 blockers) are proposed as first-line drug&#xD;
      therapy for LUTS/BPH as these agents reduce the adrenergic tone of the smooth muscle within&#xD;
      the prostate and bladder neck, thereby relieving the bladder outlet obstruction.&#xD;
&#xD;
      Tadalafil (phosphodiesterase type 5 [PDE-5] inhibitor) was approved for treating LUTS/BPH.&#xD;
      The inhibition of PDE-5leads to accumulation of cyclic guanosine monophosphate in the smooth&#xD;
      muscles of the prostate and urethra which causes their relaxation resulting in alleviation of&#xD;
      the symptoms of LUTS/BPH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom relief</measure>
    <time_frame>2 weeks</time_frame>
    <description>Decreased AUA score</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Safety and Efficacy of Tadalafil vs. Tadalafil With Sildosin in the Management of Moderately and Severely Symptomatic Patients of Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Tadalafil in moderate puts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Tadalafil in severe puts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Tadalafil with sildosin in moderate luts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>Tadalafil with sildosin in severe luts</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil 5mg</intervention_name>
    <description>Drugs</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Sildosin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Middle and old aged males&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients to be included in the study will be either:&#xD;
&#xD;
               1. diagnosis of BPH based on abdominal ultrasound or digital rectal examination.&#xD;
&#xD;
               2. Moderate IPSS Score between 8 : 19.&#xD;
&#xD;
               3. severe IPSS Score between 20 : 35.&#xD;
&#xD;
               4. post void volume &gt; 100 c.&#xD;
&#xD;
               5. prostate size 50 to 80 gm.&#xD;
&#xD;
               6. 2 or more weeks of freedom or washout from any medications known to influence&#xD;
                  LUTS before enrollment.&#xD;
&#xD;
               7. mental and physical capacity to understand and fill out the study questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. contraindications to Sildosin or Tadalafil.&#xD;
&#xD;
          2. diagnosis of prostate cancer.&#xD;
&#xD;
          3. possible presence of urinary infection, neurogenic bladder, stone bladder, refractory&#xD;
             retention, hematuria of prostate origin or any cause for surgical intervention.&#xD;
&#xD;
          4. clinically significant cardiovascular, hepatic, or renal disorders.&#xD;
&#xD;
          5. cataract surgery planned during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Being in prostate patients</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menoufia University</investigator_affiliation>
    <investigator_full_name>Mohamed Yaseen</investigator_full_name>
    <investigator_title>Menoufia governorate</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

